Options for changing therapy for persistent flu-like syndrome during treatment with interferon-Beta in patients with multiple sclerosis
2012
Abstract
Intenferon-beta1a i - beta1b (IFN-beta1a, IFN-beta1b) are medicines that affect the course of the disease and are the drugs of first choice in patients with relapsing-remitting multiple sclerosis (RR MS), but also with clinically isolated syndrome. Their effectiveness has been proven in several clinical studies that have shown a reduction in disease activity in clinical and MR parameters by about 33%.
Although these drugs significantly reduce the manifestation of side effects in clinical practice, it happens that further treatment with IFN-beta already hates patient. In the paper, we present a case report of a young woman who was the IFN-beta treatment terminated for not influence flu-like syndrome.